

REMARKS

Claims 32 and 33 are canceled herein without prejudice. Applicants expressly reserve the right to pursue protection of any or all of the subject matter of the canceled claims in a subsequent application. Claims 1, 8, 24, 31, 51-54, 58, and 59 are amended herein. Support for the amending language of claim 1 can be found throughout the specification, for instance, on page 6, lines 12-25. Claim 1 is also amended to correct form. Claims 8, 31 and 51-54 are amended to correct form. Claims 24, 58 and 59 are amended to be directed solely to the subject matter of the Examiner's Group I. No new matter is introduced by the claim amendments.

After entry of this amendment **claims 1, 7, 8, 24, 30, 31, 47, 49, and 51-59 are pending in this application.**

Restriction Requirement


Applicants hereby elect the Examiner's Group I (namely claims 1, 7, 8, 24, 30, 31, 47, 49, and 51-59, drawn to methods and products for detecting *Fusarium*) for prosecution in the instant application.

Conclusion

Consideration of the pending claims is respectfully requested. The Examiner is invited to call the undersigned if the Examiner believes that a telephone interview would facilitate substantive examination of this application.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By 
David Cash, Ph.D.
Registration No. 52,706

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446